PL3335723T3 - Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP - Google Patents
Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTPInfo
- Publication number
- PL3335723T3 PL3335723T3 PL18153673.1T PL18153673T PL3335723T3 PL 3335723 T3 PL3335723 T3 PL 3335723T3 PL 18153673 T PL18153673 T PL 18153673T PL 3335723 T3 PL3335723 T3 PL 3335723T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- variable domains
- single variable
- immunoglobulin single
- treating ttp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2013007A NL2013007B1 (en) | 2014-06-16 | 2014-06-16 | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| US201462030817P | 2014-07-30 | 2014-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3335723T3 true PL3335723T3 (pl) | 2022-07-18 |
Family
ID=51541255
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18153673.1T PL3335723T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP |
| PL15729829T PL3154569T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP |
| PL18153671T PL3366305T3 (pl) | 2014-06-16 | 2015-06-16 | Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania |
| PL18153674.9T PL3335724T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP |
| PL18153676T PL3332800T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15729829T PL3154569T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP |
| PL18153671T PL3366305T3 (pl) | 2014-06-16 | 2015-06-16 | Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania |
| PL18153674.9T PL3335724T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP |
| PL18153676T PL3332800T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10858445B2 (enExample) |
| EP (6) | EP3335723B1 (enExample) |
| JP (3) | JP6688746B2 (enExample) |
| KR (2) | KR102403388B1 (enExample) |
| CN (1) | CN106559985A (enExample) |
| AU (2) | AU2015276237B2 (enExample) |
| CA (1) | CA2952103A1 (enExample) |
| ES (5) | ES2924199T3 (enExample) |
| IL (1) | IL249540B (enExample) |
| NL (1) | NL2013007B1 (enExample) |
| PL (5) | PL3335723T3 (enExample) |
| PT (5) | PT3154569T (enExample) |
| RU (1) | RU2704444C2 (enExample) |
| SG (2) | SG10201811109PA (enExample) |
| WO (1) | WO2015193326A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CN107340225B (zh) * | 2017-07-13 | 2019-07-05 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
| MX2020008294A (es) * | 2018-02-06 | 2020-11-18 | Ablynx Nv | Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina. |
| IL302984A (en) * | 2020-11-18 | 2023-07-01 | Green Cross Corp | Adamts13 variant having increased escaping rate or activity against autoantibody |
| AU2022345251A1 (en) | 2021-09-17 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| WO2023108095A1 (en) * | 2021-12-10 | 2023-06-15 | Emory University | Polypeptides that bind to von willebrand factor (vwf) al domain or an autoinhibitory module, variants, and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| NZ513356A (en) | 1999-02-05 | 2004-01-30 | Univ Leiden | Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate |
| WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| ATE512364T1 (de) | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
| EP1565482B1 (en) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2524129C2 (ru) | 2003-01-10 | 2014-07-27 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| SI1836500T1 (sl) | 2005-01-14 | 2010-11-30 | Ablynx Nv | Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami |
| LT2444424T (lt) * | 2005-05-20 | 2018-10-25 | Ablynx N.V. | Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CN101663319A (zh) | 2007-02-21 | 2010-03-03 | 埃博灵克斯股份有限公司 | 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病 |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| US20110158996A1 (en) | 2008-03-21 | 2011-06-30 | Ablynx N.V. | Von willebrand factor specific binders and methods of use therefor |
| RU2481824C2 (ru) | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
| CN105646643A (zh) | 2008-10-29 | 2016-06-08 | 阿布林克斯公司 | 单域抗原结合性分子的纯化方法 |
| US20120321640A1 (en) | 2009-12-01 | 2012-12-20 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
| AU2011325134B2 (en) * | 2010-11-05 | 2014-10-23 | Novartis Ag | Methods of treating rheumatoid arthritis using IL-17 antagonists |
| CN103732244A (zh) | 2011-06-10 | 2014-04-16 | 巴克斯特国际公司 | 通过施用重组vwf治疗凝血疾病 |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| MX2020008294A (es) | 2018-02-06 | 2020-11-18 | Ablynx Nv | Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina. |
-
2014
- 2014-06-16 NL NL2013007A patent/NL2013007B1/en active
-
2015
- 2015-06-16 KR KR1020177001152A patent/KR102403388B1/ko active Active
- 2015-06-16 ES ES18153674T patent/ES2924199T3/es active Active
- 2015-06-16 PT PT157298290T patent/PT3154569T/pt unknown
- 2015-06-16 PL PL18153673.1T patent/PL3335723T3/pl unknown
- 2015-06-16 EP EP18153673.1A patent/EP3335723B1/en active Active
- 2015-06-16 WO PCT/EP2015/063493 patent/WO2015193326A1/en not_active Ceased
- 2015-06-16 ES ES18153676T patent/ES2831865T3/es active Active
- 2015-06-16 RU RU2017100077A patent/RU2704444C2/ru active
- 2015-06-16 US US15/319,467 patent/US10858445B2/en active Active
- 2015-06-16 ES ES15729829T patent/ES2881331T3/es active Active
- 2015-06-16 SG SG10201811109PA patent/SG10201811109PA/en unknown
- 2015-06-16 PL PL15729829T patent/PL3154569T3/pl unknown
- 2015-06-16 PT PT181536749T patent/PT3335724T/pt unknown
- 2015-06-16 EP EP18153674.9A patent/EP3335724B1/en active Active
- 2015-06-16 CN CN201580040020.4A patent/CN106559985A/zh active Pending
- 2015-06-16 JP JP2016573549A patent/JP6688746B2/ja active Active
- 2015-06-16 EP EP22172948.6A patent/EP4059513A1/en not_active Withdrawn
- 2015-06-16 PT PT181536764T patent/PT3332800T/pt unknown
- 2015-06-16 PL PL18153671T patent/PL3366305T3/pl unknown
- 2015-06-16 PL PL18153674.9T patent/PL3335724T3/pl unknown
- 2015-06-16 SG SG11201610488QA patent/SG11201610488QA/en unknown
- 2015-06-16 ES ES18153673T patent/ES2915473T3/es active Active
- 2015-06-16 KR KR1020227012546A patent/KR102568585B1/ko active Active
- 2015-06-16 EP EP15729829.0A patent/EP3154569B1/en active Active
- 2015-06-16 CA CA2952103A patent/CA2952103A1/en not_active Abandoned
- 2015-06-16 EP EP18153676.4A patent/EP3332800B1/en active Active
- 2015-06-16 PL PL18153676T patent/PL3332800T3/pl unknown
- 2015-06-16 PT PT181536731T patent/PT3335723T/pt unknown
- 2015-06-16 EP EP18153671.5A patent/EP3366305B1/en active Active
- 2015-06-16 AU AU2015276237A patent/AU2015276237B2/en active Active
- 2015-06-16 PT PT181536715T patent/PT3366305T/pt unknown
- 2015-06-16 ES ES18153671T patent/ES2843642T3/es active Active
-
2016
- 2016-12-13 IL IL249540A patent/IL249540B/en unknown
-
2018
- 2018-01-26 US US15/881,003 patent/US10919980B2/en active Active
- 2018-01-26 US US15/881,055 patent/US20180155443A1/en not_active Abandoned
- 2018-01-26 US US15/880,870 patent/US20180155440A1/en not_active Abandoned
- 2018-01-26 US US15/880,978 patent/US12269893B2/en active Active
-
2020
- 2020-01-30 JP JP2020014229A patent/JP7105260B2/ja active Active
-
2021
- 2021-05-03 AU AU2021202747A patent/AU2021202747B2/en active Active
-
2022
- 2022-07-11 JP JP2022110921A patent/JP7883399B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281755A (en) | Enhanced variable complexes of immunoglobulins | |
| IL247898A0 (en) | Anti-ox40 antibodies and methods of use | |
| IL252008A0 (en) | Methods for producing bispecific domains, variants of antibodies and their use | |
| IL250724A0 (en) | Methods for treating multiple myeloma with immunomodulatory compounds in combination with antibodies | |
| IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
| PT3335724T (pt) | Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt | |
| ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
| IL265568A (en) | Methods for treating TIM-3 elevation | |
| HK1236434A1 (en) | Methods of treating ttp with immunoglobulin single variable domains and uses thereof |